Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer.
Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer. Gynecol Oncol. 2011 May 01; 121(2):269-72.
View in:
PubMed
subject areas
Antibodies, Monoclonal
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
Antineoplastic Combined Chemotherapy Protocols
Bevacizumab
Bevacizumab
Disease-Free Survival
Disease-Free Survival
Female
Female
Humans
Humans
Middle Aged
Middle Aged
Neoplasm Recurrence, Local
Neoplasm Recurrence, Local
Neoplasms, Glandular and Epithelial
Neoplasms, Glandular and Epithelial
Ovarian Neoplasms
Ovarian Neoplasms
Paclitaxel
Paclitaxel
Retrospective Studies
Retrospective Studies
Survival Rate
Survival Rate
authors with profiles
Debra L Richardson